Citations

Clear

3042 citation(s) found for "Kumar, S".

An international survey of liver transplant business practices: Identifying best practices and areas for improvement
Patel, Madhukar S., Matevish, Lauren E. , Broering, Dieter, Chan, Albert CY, DIB, MARTÍN JAVIER, Dillon, Audrey , Heimbach, Julie K. , Khalaileh, Abed , Kumar, Sathish S. , Mehta, Goutham K., Mathur, Amit K. , Pomposelli, James J. , Watt, K.D.S., Xu, Xiao, Maluf, Daniel G. , Chan, Albert , Patel, Madhukar S. , Bröering, Dieter C. , Broering, Dieter , Chan, Albert C Y , Dib, Martin J , Dillon, Audrey A , Pomposelli, James , Watt, Kimberly, Maluf, Daniel , Selzner, Markus , Heimbach, Julie K , Selzner, Markus , Patel, Madhukar

Mayo Clinic

Liver Transplantation | February 3, 2026 | Volume: 32 | Issue: 7 | Pages: 1066-1075

10.1097/lvt.0000000000000812 | PMID 41632944 Get It

Limited information on the business practices of liver transplant (LT) centers worldwide has been published. Characterizing this data could help identify best practices as well as opportunities for improvement. As such, the International Liver Transplant Society (ILTS) Business Practice Committee conducted a global online survey of LT centers, which was sent to the ILTS membership. Questions focused on 5 main domains: transplant practice and volumes, workforce, finances, quality assessment and performance improvement, and overall program function. Data was compared across program geographic regions and transplant volume. A total of 89 discrete centers were represented, of which 76.4% were academic/university-affiliated, and about one-third each were from Europe (36.0%) and North America (31.5%). The top 3 problems programs reported were finances/funding (60.7%), adequate program support/guidance (48.3%), and transplant volumes (43.8%). In all, 59.6% of respondents felt their salary was undercompensated, consistent across geographic regions. In addition, 69.7% felt their center was not adequately funded to meet program goals, with programs in Europe (N=28/32, 87.5%) and Oceania (N=2/3, 66.7%) most impacted. Transplant surgeon retainment was noted as more difficult for lower volume programs (<50 liver transplants/year, N=13/31). Nearly half (42.7%) of all programs felt under-resourced to provide high-quality care, and the majority (80.9%) felt there was room for growth and improvement under their current model. While international concerns varied widely among LT centers, inadequate salary and center funding, low transplant and referral volumes, and staff retainment were persistent themes. Focusing on adopting region-specific best practices and developing transplant systems of care that focus on these elements is critical to provide optimal care to LT patients worldwide.
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses
Han, Younghun , Byun, Jinyoung, Cooley, Matthew A. , Shaw, Vikram R., Ahmed, Fowsiyo , Giama, Nasra H., Ali, Hawa M. , Campbell, Nellie A. , Hassan, Mohamed, Andersen, Jesper B., Ankoma-Sey, Victor, Bañales, Jesús M. , Bujanda, L. , Bathe, Oliver F. , Bekaii-Saab, Tanios S., Borad, Mitesh J., Chan, Carlos H.F. , Cleary, S., Folseraas, Trine , Galle, P R, MacInnis, Robert J., Gores, Gregory J., Houlston, Richard S., Ilyas, Sumera, Javle, Milind, Johansen, Julia S., Christensen, Troels Dreier , Kamath, Ashwin S. , Kelley, Robin Kate , Lamarca, Angela, Lammert, F, Lindsey, Stacie , Macias, Rocio I. R., Patel, Tushar, Permuth, Jennifer B., Rossi, Stephen, Sanchez, William, Smoot, Rory L., Swerdlow, Anthony J., Cao, H. Tran, Valle, Juan, Weinmann, A., Wong, Linda L. , Zimmer, Vincent, Zhu, A., Kn, Lazaridis, Juran, Brian D., Jalal, Prasun Kumar, Knox, J., Hutchinson, Amy, Hicks, Belynda, Chanock, Stephen J., Hassan, Manal M. , Amos, Christopher I., McGlynn, Katherine A., Roberts, Lewis R., Roberts, Lewis R. , Sánchez, William , Han, Younghun , Byun, Jinyoung , Byun, Jinyoung , VanLith, Caitlin J. , Roberts, Lewis R , Banales, Jesus M , Jalal, Prasun K , Chan, Carlos H F , Sanchez, William , Shaw, Vikram R. , Hatia, Rikita , Andersen, Jesper B , Ankoma‐Sey, Victor, Bekaii‐Saab, Tanios , Borad, Mitesh J. , Björkström, Niklas K. , Cleary, Sean P. , Cornillet, Martin , Galle, Peter R., Genkinger, Jeanine M. , MacInnis, Robert J. , Gores, Gregory J. , Goyal, Lipika , Houlston, Richard S. , Ilyas, Sumera I. , Javle, Milind , Johansen, Julia S., Khan, Shahid Ali , Kim, Richard D. , Kwee, Sandi Alexander , Lamarca, Angela , LaRusso, Nicholas F. , Malhi, Harmeet , Permuth, Jennifer B. , Reeves, Helen L. , Smoot, Rory L. , Swerdlow, Anthony J , Weinmann‐Menke, Julia , Zhang, Xuehong , Zimmer, Vincent , Zhu, Andrew X. , Jalal, Prasun K. , Hutchinson, Amy , Hicks, Belynda , Koshiol, Jill , Chanock, Stephen Jacob , Amos, Christopher I. , McGlynn, Katherine A.

Mayo Clinic

Hepatology | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001699 | PMID 41627892 Get It

Background and Aims: Cholangiocarcinoma (CCA) is a rare but aggressive malignancy with poorly understood genetic susceptibility. To date, genome-wide association studies (GWAS) investigating germline variants associated with CCA risk remain limited. We aimed to identify genetic risk loci for CCA and its clinical subtypes through comprehensive GWAS and post-GWAS analyses. Approach and Results: We conducted a GWAS of 2366 CCA cases and 11,750 controls of European ancestry. Genome-wide significant loci ( p <5×10 −8 ) were identified and further examined through fine-mapping, functional annotation, and HLA imputation. Subgroup analyses were conducted by CCA subtypes and primary sclerosing cholangitis (PSC) status. Cross-trait linkage disequilibrium score regression and Mendelian randomization were employed to investigate the shared genetic architecture and potential causal relationships with a diverse range of traits. We identified 1 new genome-wide significant variant, rs535777 (OR=1.44), near HLA-DRB1/DQA1 associated with CCA, and 2 variants associated with extrahepatic CCA: rs116224263 (OR=0.17) in LINC02506 at 4p15.1 and rs6914950 (OR=1.63) near HLA-DRB1/DQB1 . Stratified analyses revealed rs2395184 (OR=3.51) near HLA-DRA/DRB5 associated with PSC-related CCA, and rs142674434 (OR=2.98) in THSD7A at 7p21.3 associated with non-PSC-related CCA. HLA imputation uncovered new amino acid residues associated with disease risk. Cross-trait analyses identified shared genetic signals between CCA and anthropometric, lipidemic, lifestyle, and medical traits. Mendelian randomization supported putative causal associations for 12 traits with CCA or its subtypes. Conclusions: Our large-scale GWAS highlights new genetic variants and HLA-linked mechanisms underlying CCA susceptibility. Integrating multi-step post-GWAS approaches enhances understanding of CCA pathogenesis and may facilitate the development of risk biomarkers for early detection and precision prevention strategies.
Age and sex influence transcriptomic responses to statin therapy that control liver aging during systemic metabolic dysfunction
Umbaugh, David S. , Wang, Liuyang, Du, Kuo , Dutta, Rajesh Kumar , Oh, Seh Hoon , Karachaliou, Georgia Sofia , Suzuki, Ayako, Diehl, Anna Mae , Suzuki, Ayako , Abdelmalek, Manal F. , Suzuki, Ayako , Oh, Seh‐Hoon

Mayo Clinic

Hepatology | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001704 | PMID 41627886 Get It

Background and Aims: Older age increases susceptibility to metabolic dysfunction–associated steatotic liver disease (MASLD), but whether it impacts response to therapies, and how the therapies impact regulators of biological aging, are poorly understood. Statins inhibit the mevalonate pathway to block cholesterol biosynthesis and are widely used in MASLD patients to reduce cardiovascular disease. Whether statins prevent progression to cirrhosis is under investigation. However, the molecular effects of statins in human liver, particularly in the context of aging, remain poorly defined. Approach and Results: We analyzed liver transcriptomes and matched clinical data from 368 adults enrolled in the Duke MASLD Biorepository with a focus on age-dependent responses and the interplay between senescence and ferroptosis, a regulated death process that is constrained by the mevalonate pathway. Serum ALT, AST, and LDL cholesterol levels were lower in statin users of both sexes, particularly among older individuals. Transcriptome analyses revealed that statin use is strongly associated with suppression of senescence-related pathways. Statin use is also associated with increased activation of pathways linked to ferroptosis. Both responses persisted after propensity score matching to control for clinical confounders and were validated in an independent obese cohort. Conclusions: Age-dependent transcriptional remodeling in the liver differs in statin users and non-users. Pathways involved in senescence are suppressed while those that promote ferroptosis are induced in statin users. These results suggest that statins may suppress biological aging in MASLD by acting as senolytics and highlight the complex, context-specific roles of senescence in liver adaptation and remodeling.
Functional Changes in the Fallopian Tube: Environmental Factors, Lifestyle, Pathological Conditions and Pharmacological Agents
Roy, Opalina, Kumari, Sandhya, Adiga, Satish Kumar , Kumar, Anujith , Venkatraman, Ganesh, Kalthur, Guruprasad , Venkatraman, Ganesh , Kannan, Nagarajan , Adiga, Satish Kumar , Joshi, Manjunath Bandu , Kannan, Nagarajan

Mayo Clinic

Cells | February 2, 2026 | Volume: 15 | Issue: 3 | Pages: 269

10.3390/cells15030269 | PMID 41677632 Get It

The fallopian tubes are critical segments of the female reproductive tract and are essential for transporting gametes and embryos. It creates a conducive environment necessary for successful fertilization, early embryo development, and embryo transport. The cellular composition and function of the fallopian tube are tightly regulated by the sex hormones estradiol and progesterone. Therefore, any pathological/ metabolic condition or exposure to exogenous agents with the potential to alter endocrine levels can have a significant impact on fallopian tube function and health. This review summarizes the effects of medications, infections, pathological conditions, lifestyle choices, and environmental factors that can significantly impact the morphology, histology, cellularity, and functionality of the fallopian tube.
Efficacy and Safety of Apixaban in Cancer-Associated Thromboembolism: A Narrative Review
Aperna, Fnu, Kumar, Mahesh, Ahmad, Rimsha, Niaz, Mahnoor, Khan, Saifullah, Vakhshoori, Mehrbod, Arslan, Fatima Safi , Frishman, William H., Aronow, Wilbert S., Ahmad, Rimsha , Niaz, Mahnoor, Khan, Saifullah , Vakhshoori, Mehrbod , Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001195 | PMID 41622537 Get It

Cancer-associated venous thromboembolism (CA-VTE) is a leading, severe, and potentially life-threatening complication in patients with malignancy. Low–molecular-weight heparin has historically been the standard of care; however, direct oral anticoagulants, particularly direct factor Xa inhibitors, have emerged as effective alternatives. These agents offer the convenience of oral administration, predictable pharmacokinetics, elimination of routine laboratory monitoring, and improved adherence. Despite the expanding role of direct oral anticoagulants in CA-VTE management, concerns regarding bleeding risk—particularly in patients with gastrointestinal and genitourinary malignancies—remain central to clinical decision-making. In this narrative review, we evaluate the efficacy, safety, and clinical applicability of apixaban for the treatment and prophylaxis of CA-VTE. Current evidence from randomized controlled trials, including CARAVAGGIO and AMPLIFY, demonstrates that apixaban has noninferior efficacy compared with low–molecular-weight heparin and conventional anticoagulation strategies, with comparable or lower rates of recurrent venous thromboembolism. In addition, apixaban appears to have a favorable safety profile, with no statistically significant increase in major bleeding in selected cancer populations, including those without active gastrointestinal lesions. Apixaban’s pharmacokinetic properties, including limited renal clearance and stable drug exposure, further enhance its clinical utility in oncologic populations. However, evidence supporting apixaban use across all cancer subtypes remains limited and heterogeneous, highlighting the need for additional comparative and real-world studies.
Abstract DP020: Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage The QUANTUM Randomized Clinical Trial
Ironside, Natasha , Patrie, James, Kumar, Jeyan S. , Naamani, Kareem El, Abbas, Rawad , Becerril, Andrea Pecina, Chen, Ching-Jen, Rizvi, Tanvir , Mastorakos, Panagiotis , Naamani, Kareem El , Snyder, M. Harrison

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp020 Get It

Introduction: Optimizing patient selection and time-to-intervention will be crucial to the success of future clinical trials seeking to implement therapies and improve intracerebral hemorrhage (ICH) patient outcomes. Automated and accurate ICH and perihematomal edema (PHE) volumetry carries significant potential to strengthen trials targeting ICH and PHE expansion. Aims: The Quantification of Hematoma and Perihematomal Edema Volumes in Intracerebral Hemorrhage (QUANTUM) trial was designed with aims of (1) validating a fully automated artificial intelligence (AI) method for supratentorial, spontaneous ICH and PHE volumetry against the manual and semiautomated quantification methods and (2) establishing a model framework for the translation of AI technology through conduct of a clinical trial under the equivalence hypothesis paradigm. Methods: This trial was a prospective, randomized, clinical study with blinded outcome assessment. Six independent raters were randomized in a 1:1 ratio to ICH and PHE volumetry from non-contrast CT scans in the Virtual International Stroke Trials Archive with either the semiautomated or manual quantification method. The primary outcomes were equivalence between (1)ICH volume measurements on admission (<24h from symptom onset) for the manual versus the fully automated or the sem-automated quantification methods, and (2)PHE volume measurements on day 3 (72±12h from symptom onset) for the manual versus the fully automated or the semiautomated quantification methods. The required sample size was 126 ICH and 126 PHE measurements, based upon a significance level of 0.025 to account for the two equivalence tests. Results: The geometric mean relative discrepancies between the fully automated and the manual ICH and PHE volume measurements did not cross the pre-specified 10% equivalence margin. The geometric mean relative discrepancies between the semiautomated and the manual ICH and PHE volume measurements did cross the pre-specified 10% equivalence margin. The fully automated method (mean 10.0±2.7s/scan) was significantly faster than the manual (mean 189±199 s/scan; P <0.001) and semiautomated (mean 79±68s/scan; P <0.001) methods. Conclusions: ICH and PHE volumes quantified by AI could replace clinician measurements within a 10% error margin and with substantially greater efficiency. The semiautomated method could not replace manual measurements. This trial demonstrated feasibility of the equivalence hypothesis framework for AI validation studies.
Abstract WP108: Risk of Seizures Among Patients with Cerebral Amyloid Angiopathy – a Nationwide Retrospective Cohort Study in the United States
Abraham, Anup, Farrugia, Lynn, Kumar, Varun , Shirvan, Julia, Parikh, Neal S. , Zhang, Jie, Lin, Michelle

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.wp108 Get It

Introduction: Cerebral amyloid angiopathy (CAA) is a progressive cerebrovascular disease caused by amyloid-beta (Aβ) deposition in cerebral vasculature. While CAA is a recognized cause of intracerebral hemorrhage (ICH) and cognitive decline, emerging evidence suggests that seizures are among a broader array of CAA clinical manifestations. However, the risk of seizures and status epilepticus in CAA remains poorly characterized. This study aimed to estimate incidence of seizures and status epilepticus in CAA using real-world data. Methods: A retrospective, longitudinal study was conducted using a nationally representative sample of administrative claims from US Medicare and commercial insurance beneficiaries (2017–2024). Patients with CAA (aged > 50 years with > 1 physician encounter with a validated ICD-10 code (I68.0)) were matched 1:4 to age- and sex-matched controls. The primary outcome was occurrence of seizure, ascertained using validated ICD-10 codes during acute care; the secondary outcome was hospitalization for status epilepticus. Follow-up continued until the end of enrollment or death. Descriptive statistics summarized patient characteristics and Poisson regression estimated incidence rates with 95% CIs. Cox proportional hazards regression assessed associations between CAA and outcomes of interest vs controls, adjusted for chronic kidney disease, liver disease, prior ICH, and seizure history. Results: We included 7294 patients with CAA and 29176 controls (median age: 77 years; 53.7% women; median follow-up: 29.4 months). Patients with CAA had higher rates of prior ICH (32.4% vs 0.5%) and prior seizure (18.7% vs 1.8%) than controls. The incidence rate of seizures was higher in patients with CAA than controls: 8.1 per 100 person-years (PY; 95% CI: 7.6–8.6) vs 0.4 per 100 PY (95% CI: 0.4–0.5). In the CAA cohort, seizure incidence rate was higher for those with prior ICH than those with no ICH history: 13.6 per 100 PY (95% CI: 12.5–14.8) vs 5.7 per 100 PY (95% CI: 5.2–6.3). Status epilepticus rates were higher in patients with CAA than controls: 0.7 per 100 PY (95% CI: 0.6–0.9) vs 0.03 per 100 PY (95% CI: 0.02–0.04). Adjusted models showed that CAA was associated with higher risk of seizures (HR: 6.7, 95% CI: 5.8–7.7) and status epilepticus (HR: 8.1, 95% CI: 4.8–13.7) than controls (Table 1). Conclusions: Patients with CAA have an increased risk of seizures and status epilepticus. These findings broaden the possible clinical spectrum of CAA.
Identification of Reproducible CT‐Image Based Radiomic Features That Predict Shoulder Arthroplasty Outcomes
Rajabzadeh‐Oghaz, Hamidreza, Elwell, Josie , Schoch, Bradley, Aibinder, William R. , Gobbato, Bruno , Wessell, Daniel E. , Kumar, Vikas, Roche, Christopher , Wessell, Daniel, Roche, Christopher P , Aibinder, William R , Rajabzadeh-Oghaz, Hamidreza , Schoch, Bradley S.

Mayo Clinic

Journal of Orthopaedic Research | January 29, 2026 | Volume: 44 | Issue: 2 | Pages: No page available

10.1002/jor.70154 | PMID 41608758 Get It

ABSTRACT The goal of this radiomic analysis is to quantify the sensitivity of radiomic features on computed tomography (CT) image pre‐processing parameters and use machine learning (ML) techniques to identify the radiomic features that are highly predictive of shoulder arthroplasty outcomes. An ML framework auto‐segmented 3D masks of the deltoid muscle and scapula bone from pre‐operative CT images of 1949 primary anatomic total shoulder arthroplasty (aTSA)/reverse total shoulder arthroplasty (rTSA) patients. Radiomic features were extracted after various image pre‐processing protocols and assessed for reproducibility. The radiomic features deemed robust to image pre‐processing were used to train ML predictive outcomes models. Feature importance data were rank‐ordered to identify the radiomic features that were highly predictive of pain, motion, and function before and after aTSA/rTSA. A sensitivity analysis identified 37 deltoid muscle and 38 scapular bone radiomic features that were robust, reproducible, and unique across image pre‐processing parameters. The most predictive deltoid muscle radiomic measurements were normalized volume, elongation, flatness, fat percentage, sphericity, and max 2D diameter column. The most predictive scapular bone radiomic measurements were flatness, sphericity, elongation, max 2D diameter column, and max 2D diameter slice. Radiomic data of the deltoid and scapula were highly predictive of pain, motion, and function before and after aTSA and rTSA. Radiomic data were more predictive than patient comorbidities, diagnosis, and implant type/size data, but less predictive than pre‐operative active range of motion measurements and patient reported outcome measures, 3D measurements from planning software, or patient demographic data. Future work is required to clinically validate these radiomic features before they can be deployed in clinical decision support tools. Level of Evidence Level III, Retrospective Comparative Outcome Study.
Widaplik: A Fixed-Dose Triple Combination for Initial Hypertension Therapy
Niaz, Mahnoor, Ahmad, Rimsha , Khan, Saifullah , Kumar, Mahesh, Arslan, Fatima Safi , Hussain, Syed Sadam, Frishman, William H., Aronow, Wilbert S., Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | January 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001190 | PMID 41593840 Get It

Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, yet blood pressure control rates remain suboptimal despite the availability of effective therapies. Contemporary guidelines increasingly recommend early use of combination therapy, recognizing that most patients require multiple agents to achieve target blood pressure. Widaplik, a recently Food and Drug Administration-approved fixed-dose, single-pill triple combination of telmisartan, amlodipine, and indapamide, represents the first triple therapy approved for initial treatment of hypertension in adults likely to need multidrug therapy. This review summarizes the pharmacologic rationale for low-dose triple therapy, highlighting complementary mechanisms targeting the renin-angiotensin-aldosterone system, vascular resistance, and sodium retention. We examine evidence from pivotal phase 3 trials demonstrating rapid, sustained blood pressure reductions, higher control rates compared with dual therapy, and favorable tolerability. We also discuss safety considerations, practical limitations, and gaps in evidence, including long-term cardiovascular outcomes. Widaplik represents a paradigm shift toward simplified, early combination therapy aimed at improving hypertension control and reducing cardiovascular risk.
Model for End-Stage Liver Disease-Lactate and Lactate Clearance in Critically Ill Cirrhosis Patients With Sepsis
Shabbir, Rehma , Garrido-Trevino, Luis , O’Leary, Jacqueline G., Chaudhary, Ashok , Maiwall, Rakhi, Arora, Vinod, Tevethia, Harshvardhan V. , Sarin, Shiv K., Hall, Lauren, Ogola, Gerald O., Kamath, Patrick S., Choudhury, Ashok , O'Leary, Jacqueline G , Maiwall, Rakhi , Sarin, Shiv Kumar , Kamath, Patrick S , O’Leary, Jacqueline G. , Maiwall, Rakhi , Arora, Vinod, Ogola, Gerald , Kamath, Patrick S. , Asrani, Sumeet K.

Mayo Clinic

American Journal of Gastroenterology | January 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000003934 | PMID 41589697 Get It

INTRODUCTION: A Model for End-Stage Liver Disease-lactate (MELD-LA) score is an independent predictor of inpatient mortality and organ failure validated in more than 8,600 patients across diverse settings. However, its utility in sepsis, particularly when combined with lactate clearance (LA clearance), has not been fully evaluated. In this study, we examined the dynamic role of MELD-LA with 24-hour LA clearance as a predictor of 30-day mortality in critically ill patients with cirrhosis and sepsis. METHODS: We analyzed cirrhosis patients with sepsis admitted to the intensive care unit (ICU) in a large US healthcare system (20 hospitals) from 2014 to 2022, examining MELD-LA and LA clearance within 24 hours as predictors of 30-day mortality. We externally validated our findings in the Asian Pacific Association for the Study of the Liver-acute-on-chronic liver failure Research Consortium, a multinational Asian cohort (31 centers) from 2009 to 2019. RESULTS: A total of 3,879 cirrhosis patients with sepsis were admitted to the ICU (43.2% female, 20.5% Hispanic, 12.4% on dialysis; mean initial LA 4.5 mmol/L, MELD 20.8, MELD-LA 17.6). Survivors showed a median lactate change of −1.04 (35% clearance) compared with −0.4 (12%) for nonsurvivors. LA clearance within 24 hours was influenced by the presenting MELD-LA. In the North American cohort, ≥35% LA clearance was associated with improved 30-day survival (odds ratio 0.41, 95% CI 0.31–0.53; P < 0.001). Similarly, in the Asian Pacific Association for the Study of the Liver cohort (n = 1,259), ≥35% clearance was linked to a 60% reduction in mortality (odds ratio 0.42, 95% CI 0.28–0.62; P < 0.001). When stratified by LA clearance, patients with LA clearance of ≥35% had a higher percentage of early administration of resuscitative measures than those with LA clearance of < 10% especially regarding early antibiotic administration (82.5% vs 67.6%; P value <0.001). DISCUSSION: Early reduction in initial LA by one-third predicts 30-day mortality and may indicate treatment response in cirrhosis patients with sepsis in the ICU. Combining MELD-LA and LA clearance early enables better risk stratification and informs management.